Cargando…

Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway

BACKGROUND: Long noncoding RNAs (lncRNAs), defined as the transcripts longer than 200 nt without protein-coding capacity, have been found to be aberrantly expressed in diverse human diseases including cancer. A reciprocal translocation between chromosome 9 and 22 generates the chimeric Bcr-Abl oncog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xuefei, Yang, Jianling, Guo, Guijie, Feng, Riyue, Chen, Ke, Liao, Yuan, Zhang, Lianfeng, Sun, Liping, Huang, Shile, Chen, Ji-Long
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454664/ https://www.ncbi.nlm.nih.gov/pubmed/30961617 http://dx.doi.org/10.1186/s12943-019-1013-3

Ejemplares similares

Interaction of Abl Tyrosine Kinases with SOCS3 Impairs Its Suppressor Function in Tumorigenesis()()()
por: Feng, Riyue, et al.
Publicado: (2018)

A Critical Role of CDKN3 in Bcr-Abl-Mediated Tumorigenesis
por: Chen, Qinghuang, et al.
Publicado: (2014)

LncRNA-IUR Sponges miR-24 to Upregulate P53 in Laryngeal Squamous Cell Carcinoma
por: Wei, Cen, et al.
Publicado: (2020)

lncRNA IUR upregulates miR-34a to inhibit pancreatic adenocarcinoma cell migratory and invasive abilities
por: Li, Ren, et al.
Publicado: (2021)

IUR Soviet Branch Seminar on the Radioecology and Countermeasures
Publicado: (1991)

A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway
por: Wei, Liuya, et al.
Publicado: (2020)

De iustitia et iure = De la justicia y del derecho /
por: Soto, Domingo de, 1494-1560
Publicado: (1967)

BCR-ABL Affects STAT5A and STAT5B Differentially
por: Schaller-Schönitz, Michael, et al.
Publicado: (2014)

Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia
por: Hoelbl, Andrea, et al.
Publicado: (2010)

eIF4B is a convergent target and critical effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in Abl transformants
por: Chen, Ke, et al.
Publicado: (2016)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

lncRNA expression signatures in response to enterovirus 71 infection
por: Yin, Zhixin, et al.
Publicado: (2013)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Evaluation of Stat5 as a potential drug target in bcr/abl-induced leukemias
por: Hölbl, Andrea, et al.
Publicado: (2008)

PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis
por: Berger, A, et al.
Publicado: (2014)

Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia
por: Berger, Angelika, et al.
Publicado: (2014)

Signal Transducer and Activator of Transcription (STAT)5 Activation by BCR/ABL Is Dependent on Intact Src Homology (SH)3 and SH2 Domains of BCR/ABL and Is Required for Leukemogenesis
por: Nieborowska-Skorska, Malgorzata, et al.
Publicado: (1999)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

A novel imatinib-upregulated long noncoding RNA plays a critical role in inhibition of tumor growth induced by Abl oncogenes
por: Ma, Yun, et al.
Publicado: (2022)

Las relecciones De Indis y De iure belli. Edición y nota preliminar de Javier Malagón Barceló.
por: Vitoria, Francisco de, 1486?-1546
Publicado: (1963)

BCR: a new target in resistance mediated by BCR/ABL-315I?
por: Haberbosch, Isabella, et al.
Publicado: (2016)

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

IGF-IR determines the fates of BCR/ABL leukemia
por: Xie, Jingjing, et al.
Publicado: (2015)

STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia
por: Warsch, Wolfgang, et al.
Publicado: (2012)

Trifolium Repens Blocks Proliferation in Chronic Myelogenous Leukemia via the BCR-ABL/STAT5 Pathway
por: Sarno, Federica, et al.
Publicado: (2020)

Thymoquinone Induces Downregulation of BCR-ABL/JAK/STAT Pathway and Apoptosis in K562 Leukemia Cells
por: Al-Rawashde, Futoon Abedrabbu, et al.
Publicado: (2021)

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
por: Deng, Xianming, et al.
Publicado: (2010)

An In-House Method for Molecular Monitoring of BCR-ABL
por: Sercan, Hakkı Ogün, et al.
Publicado: (2012)

Depression of oncogenecity by dephosphorylating and degrading BCR-ABL
por: Gao, Miao, et al.
Publicado: (2016)

Targeting the PTP1B‐Bcr‐Abl1 interaction for the degradation of T315I mutant Bcr‐Abl1 in chronic myeloid leukemia
por: Elgehama, Ahmed, et al.
Publicado: (2022)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
por: Lan, Xiaoying, et al.
Publicado: (2016)

Twins with different personalities: STAT5B—but not STAT5A—has a key role in BCR/ABL-induced leukemia
por: Kollmann, Sebastian, et al.
Publicado: (2019)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)

Retraction Note: Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin
por: Wu, L. X., et al.
Publicado: (2020)

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Effect of Ras Inhibition in Hematopoiesis and BCR/ABL Leukemogenesis
por: Baum, Karina J, et al.
Publicado: (2008)

Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus
por: Huang, Zheng-Lan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_k76cm9fjvmfueujdu48c4hmeff